Wave Life Sciences Ltd (NASDAQ:WVE) has been given a consensus recommendation of “Buy” by the nine research firms that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, five have assigned a buy rating and two have assigned a strong buy rating to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $58.40.

Several brokerages recently commented on WVE. BidaskClub lowered shares of Wave Life Sciences from a “strong-buy” rating to a “buy” rating in a report on Thursday, June 21st. ValuEngine raised shares of Wave Life Sciences from a “buy” rating to a “strong-buy” rating in a report on Monday, July 2nd. Mizuho set a $65.00 price target on shares of Wave Life Sciences and gave the stock a “buy” rating in a report on Friday, June 29th. Stifel Nicolaus began coverage on shares of Wave Life Sciences in a report on Monday, August 6th. They issued a “buy” rating and a $56.00 price target for the company. Finally, HC Wainwright reissued a “buy” rating and issued a $49.00 price target on shares of Wave Life Sciences in a report on Monday, July 23rd.

Shares of NASDAQ:WVE traded up $0.20 during trading on Friday, hitting $53.05. 1,081 shares of the stock traded hands, compared to its average volume of 113,747. The company has a debt-to-equity ratio of 0.05, a current ratio of 6.11 and a quick ratio of 6.11. The firm has a market cap of $1.55 billion, a price-to-earnings ratio of -13.79 and a beta of 0.96. Wave Life Sciences has a 52-week low of $21.00 and a 52-week high of $55.95.

Wave Life Sciences (NASDAQ:WVE) last posted its earnings results on Thursday, August 9th. The company reported ($1.23) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.88). The firm had revenue of $4.88 million for the quarter, compared to analysts’ expectations of $7.38 million. Wave Life Sciences had a negative net margin of 1,473.26% and a negative return on equity of 91.88%. sell-side analysts anticipate that Wave Life Sciences will post -4.99 earnings per share for the current fiscal year.

In related news, insider Chris Francis sold 24,496 shares of the business’s stock in a transaction on Monday, July 9th. The shares were sold at an average price of $37.27, for a total value of $912,965.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 44.20% of the stock is currently owned by insiders.

Institutional investors and hedge funds have recently made changes to their positions in the business. Spark Investment Management LLC boosted its stake in Wave Life Sciences by 38.1% during the 2nd quarter. Spark Investment Management LLC now owns 155,600 shares of the company’s stock worth $5,951,000 after purchasing an additional 42,900 shares during the last quarter. UBS Group AG boosted its position in shares of Wave Life Sciences by 26.0% during the 1st quarter. UBS Group AG now owns 8,356 shares of the company’s stock valued at $335,000 after acquiring an additional 1,723 shares during the last quarter. BB Biotech AG boosted its position in shares of Wave Life Sciences by 27.0% during the 2nd quarter. BB Biotech AG now owns 1,137,885 shares of the company’s stock valued at $43,524,000 after acquiring an additional 241,789 shares during the last quarter. DAFNA Capital Management LLC acquired a new position in shares of Wave Life Sciences during the 1st quarter valued at about $1,780,000. Finally, Boxer Capital LLC boosted its position in shares of Wave Life Sciences by 17.8% during the 2nd quarter. Boxer Capital LLC now owns 1,590,600 shares of the company’s stock valued at $60,840,000 after acquiring an additional 240,600 shares during the last quarter. 83.43% of the stock is currently owned by institutional investors.

About Wave Life Sciences

Wave Life Sciences Ltd., a biotechnology company, designs, develops, and commercializes nucleic acid therapeutic candidates for genetically defined diseases by utilizing proprietary synthetic chemistry drug development platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.

Featured Story: How Do You Calculate Return on Equity (ROE)?

Analyst Recommendations for Wave Life Sciences (NASDAQ:WVE)

Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.